SAN FRANCISCO--(BUSINESS WIRE)--Synosia Therapeutics today announced the presentation of data from a phase 2a clinical study of the company’s adenosine 2a (A2a) receptor antagonist (SYN-115) in ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback